Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS)
…, E Zucchi, A Gessani, M Ceroni, A Chio, R D'Amico… - BMJ open, 2019 - bmjopen.bmj.com
Introduction Disruptions of proteasome and autophagy systems are central events in
amyotrophic lateral sclerosis (ALS) and support the urgent need to find therapeutic compounds …
amyotrophic lateral sclerosis (ALS) and support the urgent need to find therapeutic compounds …
Evaluating non-randomised intervention studies.
OBJECTIVES: To consider methods and related evidence for evaluating bias in non-randomised
intervention studies. DATA SOURCES: Systematic reviews and methodological papers …
intervention studies. DATA SOURCES: Systematic reviews and methodological papers …
Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries
DP Taggart, R D'Amico, DG Altman - The Lancet, 2001 - thelancet.com
Background Coronary artery bypass grafting (CABG) is the commonest major operation in
most developed countries. A single internal mammary artery (IMA) graft has proven survival …
most developed countries. A single internal mammary artery (IMA) graft has proven survival …
Trastuzumab containing regimens for early breast cancer
…, V Pistotti, V Guarneri, R D'Amico - Cochrane database …, 2012 - cochranelibrary.com
Background Approximately one‐fifth of women who develop early breast cancer have HER2‐positive
tumours, which if untreated, have a worse prognosis than HER2‐negative tumours. …
tumours, which if untreated, have a worse prognosis than HER2‐negative tumours. …
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study
G Ferrara, M Losi, R D'Amico, P Roversi, R Piro… - The Lancet, 2006 - thelancet.com
Background Two commercial blood assays for the diagnosis of latent tuberculosis infection—T-SPOT.TB
and QuantiFERON-TB Gold—have been separately compared with the …
and QuantiFERON-TB Gold—have been separately compared with the …
[PDF][PDF] Indirect comparisons of competing interventions
Background The randomised controlled trial (RCT) is the most valid design for evaluating
the relative efficacy of healthcare technology. However, many competing interventions have …
the relative efficacy of healthcare technology. However, many competing interventions have …
Selenium for preventing cancer
…, MPA Zeegers, M Horneber, R D'Amico… - Cochrane database …, 2018 - cochranelibrary.com
Background This review is the third update of the Cochrane review" Selenium for preventing
cancer". Selenium is a naturally occurring element with both nutritional and toxicological …
cancer". Selenium is a naturally occurring element with both nutritional and toxicological …
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition)
…, J Clark, M Clarke, D Cook, R D'Amico… - Journal of …, 2009 - scholars.uthscsa.edu
… Berlin, Jocalyn Clark, Mike Clarke, Deborah Cook, Roberto D'Amico, Jonathan J. Deeks,
PJ Devereaux, Kay Dickersin, Matthias Egger, Edzard Ernst, Peter C. GøtzscheJeremy …
PJ Devereaux, Kay Dickersin, Matthias Egger, Edzard Ernst, Peter C. GøtzscheJeremy …
Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care
R D'Amico, S Pifferi, V Torri, L Brazzi… - Cochrane Database …, 2009 - cochranelibrary.com
Background Pneumonia is an important cause of mortality in intensive care units (ICUs).
The incidence of pneumonia in ICU patients ranges between 7% and 40%, and the crude …
The incidence of pneumonia in ICU patients ranges between 7% and 40%, and the crude …
[PDF][PDF] Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2–positive operable breast cancer: results of the …
…, L Marini, F Piacentini, R D'Amico… - Journal of clinical …, 2012 - researchgate.net
Purpose This is a noncomparative, randomized, phase II trial of preoperative taxane-anthracycline
in combination with trastuzumab, lapatinib, or combined trastuzumab plus lapatinib in …
in combination with trastuzumab, lapatinib, or combined trastuzumab plus lapatinib in …